Novartis Q3 profit swells as oncology drugs drive growth
Source: SeekingAlpha
2025-10-28 04:13:20 ET
More on Novartis
- Novartis' Deal For Avidity And Its Late-Stage Muscle Disease Assets Has Caveats
- Novartis AG (NVS) M&A Call Transcript
- Novartis' Avidity Deal: Growth Accretive, Multiple Gated By Execution
- Novartis reports mixed Q3 results; reaffirms FY25 outlook
- Novartis Q3 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Novartis Q3 profit swells as oncology drugs drive growth
Tourmaline Bio Inc.
NASDAQ: TRML
TRML Trading
0.27% G/L:
$47.98 Last:
458,710 Volume:
$47.98 Open:
TRML Latest News
October 17, 2025 11:28:00 am
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HSII, VECO, CMA, TRML on Behalf of Shareholders
October 07, 2025 12:15:00 pm
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ETNB, TRML, CORZ, BRNS on Behalf of Shareholders
September 16, 2025 11:50:00 am
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AL, TRML, SOL on Behalf of Shareholders
TRML Stock Data
$1,232,715,019
15,877,822
N/A
136
N/A
Biotechnology & Life Sciences
Healthcare
US
New York
